EPS for BioXcel Therapeutics, Inc. (BTAI) Expected At $-0.35

July 14, 2018 - By Robert Reynolds

Analysts expect BioXcel Therapeutics, Inc. (NASDAQ:BTAI) to report $-0.35 EPS on August, 13.After having $-0.37 EPS previously, BioXcel Therapeutics, Inc.’s analysts see -5.41 % EPS growth. The stock decreased 6.50% or $0.76 during the last trading session, reaching $10.94. About 67,208 shares traded or 59.86% up from the average. BioXcel Therapeutics, Inc. (NASDAQ:BTAI) has 0.00% since July 14, 2017 and is . It has underperformed by 12.57% the S&P500.

BioXcel Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on novel artificial intelligence drug development in the fields of neuroscience and immuno-oncology in the United States. The company has market cap of $171.16 million. The firm is involved in developing BXCL501, a sublingual thin film formulation of dexmedetomidine designed for acute treatment of agitation resulting from neurological and psychiatric disorders; and BXCL701, an immuno-oncology agent designed for the treatment of prostate and pancreatic cancers. It currently has negative earnings. It is also developing BXCL502, a novel approach to the treatment of symptoms resulting from neurological disorders; and BXCL702, an immuno-oncology agent for hematological malignancies.

More notable recent BioXcel Therapeutics, Inc. (NASDAQ:BTAI) news were published by: Benzinga.com which released: “41 Biggest Movers From Yesterday” on July 11, 2018, also Benzinga.com with their article: “44 Biggest Movers From Yesterday” published on July 12, 2018, Nasdaq.com published: “BioXcel Therapeutics Forms Neuroscience Clinical Advisory Board to Support Global Development of BXCL501” on July 10, 2018. More interesting news about BioXcel Therapeutics, Inc. (NASDAQ:BTAI) were released by: Nasdaq.com and their article: “BioXcel Therapeutics Reports Positive Results from Phase 1b Trial of Intravenously-dosed Dexmedetomidine …” published on June 27, 2018 as well as Investorplace.com‘s news article titled: “7 Megatrend Stocks With Long-Term Upside Potential” with publication date: July 03, 2018.

BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.